Progenics reports outcome of OSPREY 2301 trial of PyL™

Posted on October 5, 2018 by Sitemaster

In a media release issued earlier this morning, Progenics Pharmaceuticals has announced the outcome of a Phase II/III trial of their proprietary, PSMA-targeted imaging agent PyL (also known as 18F-DCFPyL) for identification of prostate cancer. … READ MORE …

Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: , , , , | 8 Comments »

Trial of new imaging agent nears completion

Posted on June 26, 2018 by Sitemaster

Early this morning, Progenics Pharmaceuticals announced completion of enrollment of patients in the Phase II/III OSPREY trial of a new PSMA-targeted PET/CT imaging agent for detection of prostate cancer. … READ MORE …

Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: , , , , | 1 Comment »

  • Donate

  • PCaI’s ASVSG

    If you are on or thinking about active surveillance (AS) as a way to manage your low-risk prostate cancer, you may want to join Prostate Cancer International’s Active Surveillance Virtual Support Group.

  • CureTalks on PCa

    Our most recent CureTalk on Prostate Cancer (on February 21 this year)  features Eli Van Allen, MD, of the Broad Institute and the Dana-Farber Cancer Center, talking about the new “Metastatic Prostate Cancer Project” and how you can become part of the solution.

    For access to the full list of CureTalks on Prostate Cancer, please click here.

  • Disclaimer

    News and information provided on this site should not be used for diagnosing or treating any health problem or disease.

    The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.

  • Hot Posts …

  • … and Archives